Patents Represented by Attorney, Agent or Law Firm David M. Stemerick
-
Patent number: 8318939Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.Type: GrantFiled: February 18, 2010Date of Patent: November 27, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Qing Dong, Bheema R. Paraselli, Nicholas Scorah, Michael B. Wallace, Jeffrey A. Stafford
-
Patent number: 8293901Abstract: Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: GrantFiled: December 18, 2007Date of Patent: October 23, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Qing Dong, Nicholas Scorah, Steven W Kaldor
-
Patent number: 8268819Abstract: The present invention relates to intermediates of the formula wherein G1 is N; G2 is selected from the group consisting of C?O and CH2; X is a halogen; and the other groups are defined herein.Type: GrantFiled: March 26, 2012Date of Patent: September 18, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Bohan Jin, Nicholas Scorah, Qing Dong
-
Patent number: 8202990Abstract: The present invention relates generally to processes of making 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide and Form A of 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide.Type: GrantFiled: September 25, 2008Date of Patent: June 19, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Christopher McBride, Zhe Nie
-
Patent number: 8163755Abstract: The present invention provides mTOR inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods of making the compounds and intermediates thereof; and methods of using the compounds.Type: GrantFiled: August 26, 2010Date of Patent: April 24, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Bohan Jin, Nicholas Scorah, Qing Dong
-
Patent number: 8088783Abstract: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(pyrimidinylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.Type: GrantFiled: April 7, 2011Date of Patent: January 3, 2012Inventors: Qing Dong, Stephen W. Kaldor
-
Patent number: 8071766Abstract: The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: GrantFiled: January 30, 2009Date of Patent: December 6, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Young K. Chen, Erick Co, Prasuna Guntupalli, John D. Lawson, Wolfgang Reinhard Ludwig Notz, Jeffrey A. Stafford, Huong-Thu Ton-Nu
-
Patent number: 8063066Abstract: Compounds are provided for use with MEK that comprise: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: GrantFiled: March 17, 2008Date of Patent: November 22, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Qing Dong, Toufiko Kanounl, Michael B. Wallace
-
Patent number: 8030317Abstract: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: GrantFiled: December 18, 2007Date of Patent: October 4, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Qing Dong, Stephen W. Kaldor
-
Patent number: 8026234Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: GrantFiled: September 24, 2008Date of Patent: September 27, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Takashi Ichikawa, Stephen W. Kaldor
-
Patent number: 8022057Abstract: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: GrantFiled: November 7, 2008Date of Patent: September 20, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Qing Dong, Toufike Kanouni, Michael B. Wallace
-
Patent number: 8003785Abstract: The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.Type: GrantFiled: June 16, 2009Date of Patent: August 23, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Jianping Cai, Shaoqing Chen, Xin-Jie Chu, Kin-Chun Luk, Steven Gregory Mischke, Hongmao Sun, Peter Michael Wovkulich
-
Patent number: 7943626Abstract: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.Type: GrantFiled: January 5, 2010Date of Patent: May 17, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Qing Dong, Stephen W. Kaldor
-
Patent number: 7943659Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.Type: GrantFiled: October 31, 2007Date of Patent: May 17, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Mark E. Adams, Qing Dong, Michael B. Wallace
-
Patent number: 6620940Abstract: The present invention relates to 3-chloro-4-halo-1,2,5-thiadiazole compounds, a method of producing novel mono- and di-substituted-1,2,5-thiadiazoles therefrom, as well as mono- and di-substituted -1,2,5-thiadiazoles.Type: GrantFiled: September 27, 2000Date of Patent: September 16, 2003Assignee: Eli Lilly and CompanyInventor: Roger Lewis Robey
-
Patent number: 6559171Abstract: The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo[2.2.1]heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition enhancement.Type: GrantFiled: November 1, 2001Date of Patent: May 6, 2003Assignee: Eli Lilly and CompanyInventors: Charles Howard Mitch, Steven James Quimby
-
Patent number: 6541668Abstract: The present invention provides processes for the preparation of 3-aryloxy-3-arylpropylamines and intermediates thereof using an nucleophilic aromatic displacement in 1,3-dimethyl-2-imidazolidinone or N-methylpyrrolidinone.Type: GrantFiled: September 12, 2001Date of Patent: April 1, 2003Assignee: Eli Lilly and CompanyInventors: Douglas Patton Kjell, Kurt Thomas Lorenz
-
Patent number: 6429317Abstract: The present invention provides novel indane-like compounds which can be useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor. The invention provides formulations and methods for using the novel compounds.Type: GrantFiled: September 5, 2000Date of Patent: August 6, 2002Assignee: Eli Lilly and CompanyInventors: Sean P. Hollinshead, Michael A. Staszak, John S. Ward, Joseph W. Wilson, Bret E. Huff, Philip F. Hughes, Jose S. Mendoza, Charles H. Mitch
-
Patent number: 6395735Abstract: The present invention provides novel indane-like compounds which can be useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor. The invention provides formulations and methods for using the novel compounds.Type: GrantFiled: December 19, 2000Date of Patent: May 28, 2002Assignee: Eli Lilly and CompanyInventors: Sean Patrick Hollinshead, Philip Floyd Hughes, Jose Serafin Mendoza, Joseph Wendell Wilson, Bret Eugene Huff, Charles Howard Mitch, Michael Alexander Staszak, John Stanley Ward
-
Patent number: 6284771Abstract: The present invention provides a method for treating a condition selected from the group consisting of schizophrenia, schizoaffective disorder, and schizophreniform disorder in a patient using a Compound (I).Type: GrantFiled: April 3, 2000Date of Patent: September 4, 2001Assignee: Eli Lilly and CompanyInventors: Charles H. Mitch, Per Sauerberg, Harlan E. Shannon